Literature DB >> 24761809

'Double-Hit' cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients.

Daniel J Landsburg1, Sunita D Nasta, Jakub Svoboda, Jennifer J D Morrissette, Stephen J Schuster.   

Abstract

'Double-Hit' (DH) B cell non-Hodgkin lymphomas are characterized by the presence of a MYC rearrangement and additional rearrangement(s) most commonly involving BCL2 and/or BCL6. Patients with DH lymphomas are unlikely to achieve long-term survival when treated with standard immunochemotherapy alone. DH gene rearrangements can be identified through metaphase karyotyping or more sensitive fluorescence in situ hybridization (FISH), although the latter is not routinely performed. We report 53 cases of B cell lymphoma that underwent diagnostic metaphase karyotying or FISH for MYC rearrangements. DH lymphoma was detected in 17 cases. No baseline factor, including age, serum lactate dehydrogenase, stage, International Prognostic Index or histology predicted for DH status. The median overall survival was significantly shorter for DH compared to non-DH lymphoma patients (8·2 vs. 56·8 months, P < 0·001). DH status retained the most statistically significant association with overall survival on multivariate Cox regression analysis. DH status could not be inferred by baseline disease- or patient-related characteristics and was most predictive of overall survival in this cohort of B cell lymphoma patients. These findings support the practice of routine performance of FISH for DH gene rearrangements on B cell lymphoma specimens in order to effectively identify DH patients who may benefit from risk-adapted therapy.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  MYC; chemotherapy; fluorescence in situ hybridization; survival; ‘Double-Hit’ lymphoma

Mesh:

Year:  2014        PMID: 24761809     DOI: 10.1111/bjh.12901

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  15 in total

1.  Molecular Risk Stratification in Aggressive B-Cell Lymphomas.

Authors:  Zachary A K Frosch; Daniel J Landsburg
Journal:  J Clin Oncol       Date:  2020-04-02       Impact factor: 44.544

Review 2.  Double-Hit Large B Cell Lymphoma.

Authors:  Yousef Khelfa; Yehuda Lebowicz; Muhammad Omer Jamil
Journal:  Curr Oncol Rep       Date:  2017-09-26       Impact factor: 5.075

Review 3.  Current challenges and novel treatment strategies in double hit lymphomas.

Authors:  Mary Ann Anderson; Alpha Tsui; Meaghan Wall; David C S Huang; Andrew W Roberts
Journal:  Ther Adv Hematol       Date:  2016-02

4.  Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.

Authors:  Florian Scherer; David M Kurtz; Aaron M Newman; Henning Stehr; Alexander F M Craig; Mohammad Shahrokh Esfahani; Alexander F Lovejoy; Jacob J Chabon; Daniel M Klass; Chih Long Liu; Li Zhou; Cynthia Glover; Brendan C Visser; George A Poultsides; Ranjana H Advani; Lauren S Maeda; Neel K Gupta; Ronald Levy; Robert S Ohgami; Christian A Kunder; Maximilian Diehn; Ash A Alizadeh
Journal:  Sci Transl Med       Date:  2016-11-09       Impact factor: 17.956

Review 5.  The Role of c-MYC in B-Cell Lymphomas: Diagnostic and Molecular Aspects.

Authors:  Lynh Nguyen; Peter Papenhausen; Haipeng Shao
Journal:  Genes (Basel)       Date:  2017-04-05       Impact factor: 4.096

6.  Double-hit lymphomas: clinical, morphological, immunohistochemical and cytogenetic study in a series of Brazilian patients with high-grade non-Hodgkin lymphoma.

Authors:  Cristiano Claudino Oliveira; Helena Maciel-Guerra; Luan Kucko; Eric Jun Hirama; Américo Delgado Brilhante; Francisco Carlos Quevedo; Isabela Werneck da Cunha; Fernando Augusto Soares; Ligia Niero-Melo; Patrícia Pintor Dos Reis; Maria Aparecida Custodio Domingues
Journal:  Diagn Pathol       Date:  2017-01-07       Impact factor: 2.644

7.  Cutaneous presentation of Double Hit Lymphoma: A Case Report With Review of the Literature.

Authors:  Yousef Khelfa; Yehuda Lebowicz
Journal:  J Investig Med High Impact Case Rep       Date:  2016-04-08

8.  The prognosis of MYC translocation positive diffuse large B-cell lymphoma depends on the second hit.

Authors:  Alexandra Clipson; Sharon Barrans; Naiyan Zeng; Simon Crouch; Nicholas F Grigoropoulos; Hongxiang Liu; Sylvia Kocialkowski; Ming Wang; Yuanxue Huang; Lisa Worrillow; John Goodlad; Jenny Buxton; Michael Neat; Paul Fields; Bridget Wilkins; John W Grant; Penny Wright; Hesham Ei-Daly; George A Follows; Eve Roman; A James Watkins; Peter W M Johnson; Andrew Jack; Ming-Qing Du
Journal:  J Pathol Clin Res       Date:  2015-03-30

9.  Advancing the management of double hit lymphoma.

Authors:  Daniel J Landsburg
Journal:  Oncotarget       Date:  2017-09-09

10.  Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas.

Authors:  Ivonne Vazquez; Natalia Papaleo; Eugenia Garcia; Marta Salido; Antonio Salar; Silvia Hernandez; Xavier Calvo; Luis Colomo
Journal:  Cancers (Basel)       Date:  2020-04-05       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.